This site uses cookies to ensure the best viewing experience for our readers.
Life Sciences Venture Fund aMoon Appoints Fourth Partner

Brief

Life Sciences Venture Fund aMoon Appoints Fourth Partner

Tomer Berkovitz, who served as aMoon’s managing director and CFO, was appointed partner

Hagar Ravet | 18:18, 02.05.19
Israel-based life sciences, healthcare, and technology venture capital firm aMoon announced Thursday the appointment of Tomer Berkovitz to partner. Berkovitz formerly served as aMoon’s managing director and chief financial officer. He joins existing partners Isaac Devash, Todd Sone, and Yair Schindel.

For daily updates, subscribe to our newsletter by clicking here.

In March, aMoon announced the closing of its second fund, aMoon II, at $660 million. With close to $1 billion under management, it the largest health tech fund operating in Israel today. AMoon was founded in 2016 by Schindel, the former CEO of an Israeli government agency in charge of pushing forward digital initiatives, and Marius Nacht, the co-founder of firewall pioneer Check Point Software Technologies Ltd. Its first fund was backed exclusively by Nacht. AMoon's current portfolio companies include gut microbiome analysis company DayTwo Ltd., cancer diagnosis startup Ibex Medical Analytics Ltd., and medical analytics company Zebra Medical Vision Ltd.

As partner, Berkovitz will lead new investments as well as spearhead strategic collaborations with global finance enterprises, aMoon said in a statement.

AMoon partners Devash (left) , Sone, Schindel, and Berkovitz. Photo: PR AMoon partners Devash (left) , Sone, Schindel, and Berkovitz. Photo: PR AMoon partners Devash (left) , Sone, Schindel, and Berkovitz. Photo: PR

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS